Vanessa L. Ford

Array ( [id] => 17749680 [patent_doc_number] => 20220227884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => COMPLEMENT INHIBITION FOR IMPROVED NERVE REGENERATION [patent_app_type] => utility [patent_app_number] => 17/713675 [patent_app_country] => US [patent_app_date] => 2022-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15088 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17713675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19447408 [patent_doc_number] => 20240307538 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => IMMUNE CELL WHICH HAS AN FC RECEPTOR ON ITS SURFACE AND TO WHICH IS GRAFTED A HYBRID MOLECULE COMPRISING AN ANTIBODY FC FRAGMENT AND AT LEAST ONE FIBRIN-DERIVED CITRULLINE PEPTIDE, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/551156 [patent_app_country] => US [patent_app_date] => 2022-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18626 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18551156 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17913255 [patent_doc_number] => 20220315650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/683888 [patent_app_country] => US [patent_app_date] => 2022-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36893 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17683888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17640681 [patent_doc_number] => 20220168419 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS [patent_app_type] => utility [patent_app_number] => 17/673034 [patent_app_country] => US [patent_app_date] => 2022-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27629 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17673034 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19049342 [patent_doc_number] => 20240091311 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES [patent_app_type] => utility [patent_app_number] => 18/275849 [patent_app_country] => US [patent_app_date] => 2022-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8978 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18275849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18077403 [patent_doc_number] => 20220403015 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => TREATMENT OF CONGESTIVE HEART FAILURE AND OTHER CARDIAC DYSFUNCTION USING A GDF15 MODULATOR [patent_app_type] => utility [patent_app_number] => 17/649732 [patent_app_country] => US [patent_app_date] => 2022-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13574 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17649732 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034183 [patent_doc_number] => 20240083998 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => PREVENTION AND TREATMENT OF STEROID-RESISTANT OR GUT GRAFT-VERSUS-HOST DISEASE (GVHD) [patent_app_type] => utility [patent_app_number] => 18/270706 [patent_app_country] => US [patent_app_date] => 2022-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19894 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18270706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18956568 [patent_doc_number] => 20240044895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => IDENTIFICATION OF SARS-COV-2 EPITOPES DISCRIMINATING COVID-19 INFECTION FROM CONTROL AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/245868 [patent_app_country] => US [patent_app_date] => 2021-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245868 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18986487 [patent_doc_number] => 20240058456 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => MOLECULES WITH SOLUBILITY TAG AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 18/245819 [patent_app_country] => US [patent_app_date] => 2021-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 83195 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245819 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895265 [patent_doc_number] => 20240010750 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => NOVEL ANTI-A2AP ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/026089 [patent_app_country] => US [patent_app_date] => 2021-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29897 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18026089 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18725833 [patent_doc_number] => 20230340055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => GLYCOSYLATED IL-2 PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/043319 [patent_app_country] => US [patent_app_date] => 2021-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 77477 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18305880 [patent_doc_number] => 20230109780 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => ANTI-NGF ANTIBODY AND ANTIGEN-BINDING FRAGMENT THEREOF, PREPARATION METHOD, AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/906190 [patent_app_country] => US [patent_app_date] => 2021-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9871 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17906190 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18418632 [patent_doc_number] => 20230173090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE RECEPTOR ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/928850 [patent_app_country] => US [patent_app_date] => 2021-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28341 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17928850 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18536118 [patent_doc_number] => 20230241205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => SARS-COV-2 IMMUNODOMINANT PEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/009826 [patent_app_country] => US [patent_app_date] => 2021-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47294 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -71 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18009826 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18628225 [patent_doc_number] => 20230287078 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => Methods and Compositions for Modulating Toll-Like Receptor 5 (TLR5) Function [patent_app_type] => utility [patent_app_number] => 18/000470 [patent_app_country] => US [patent_app_date] => 2021-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15677 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000470 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18530256 [patent_doc_number] => 20230235326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING OCULAR DISEASES [patent_app_type] => utility [patent_app_number] => 18/000538 [patent_app_country] => US [patent_app_date] => 2021-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18694 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597226 [patent_doc_number] => 20230272020 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => MODIFIED SEMAPHORIN 3A, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/928685 [patent_app_country] => US [patent_app_date] => 2021-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14684 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17928685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18921461 [patent_doc_number] => 20240024465 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => ALLERGEN PREPARATION [patent_app_type] => utility [patent_app_number] => 18/040357 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10194 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18040357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18483656 [patent_doc_number] => 20230210957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => PHARMACEUTICAL COMPOSITION IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION INCLUDING AT LEAST A RAPID ACTING INSULIN ANALOG AND A GLUCAGON SUPPRESSOR WITH PRANDIAL ACTION [patent_app_type] => utility [patent_app_number] => 17/928502 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7915 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17928502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18420161 [patent_doc_number] => 20230174622 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => EPIDERMAL GROWTH FACTOR RECEPTOR [patent_app_type] => utility [patent_app_number] => 17/998447 [patent_app_country] => US [patent_app_date] => 2021-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21141 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998447 [rel_patent_id] =>[rel_patent_doc_number] =>)